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Long term impact of the WHI studies 
on information-seeking and decision-making 
in menopause symptoms management: 
a longitudinal analysis of questions 
to a medicines call centre
Rifani B. Natari1,2 , Samantha A. Hollingworth1* , Alexandra M. Clavarino1,3 , Kaeleen D. Dingle4  and 
Treasure M. McGuire1,5,6  
Abstract 
Background: While women are taking a greater role in decisions about menopause symptom management, the 
legacy of the Women’s Health Initiative (WHI) studies persist. Despite hormone therapy (HT) being effective in reduc-
ing all-cause mortality, many women seeking relief of menopausal symptoms exaggerate HT harms and overstate 
the perceived benefits or ignore the risks of alternative therapies. We aimed to explore the longitudinal impact of the 
widely-publicised WHI 2002 study on women’s information-seeking and describe determinants of decision-making 
about managing menopausal symptoms.
Methods: In a longitudinal analysis of both quantitative and qualitative data, we explored consumer questions about 
menopause-related medicines received by two Australian medicines call centres (1996–2010) before, during, and 
after WHI 2002. We analysed calls by age and gender of caller and patient, their relationship, postcode, enquiry type, 
and motivation to help-seek. We compared calls regarding HT and herbal medicines (HM) with the rest of calls, and 
thematically analysed question narratives across the three time-periods.
Results: There were 1,829 menopause-related calls received of over this time-period, with a call surge, primarily from 
women in their mid-fifties, in the two months after the WHI 2002 publication. Two in three calls were motivated by 
negative media reports as women sought support for decision-making, primarily reassurance to cease HT. While HT 
safety concerns persisted for eight years post-publication, the nature of information-seeking changed over time. Call-
ers subsequently sought reassurance to use menopause treatments together with their other medicines; and pursued 
HT substitutes, including HM, in response to HT product discontinuation.
Conclusions: Women sought information or reassurance to support a decision, based on dynamic changes in 
internal (symptom or risk intolerance, attitude towards menopause and treatment preferences) and external factors 
(perceived source trust and changes in treatment availability). In assessing HT benefit versus risk, women tend to 
overestimate risk with HT safety concerns persisting over time. Decision-making in managing menopause symptoms 
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Background
Menopause is a natural and unique experience for every 
woman [1]; some easily pass through, while others have 
a difficult transition [1]. Vasomotor symptoms (VMS) are 
most common during the transition (prevalence 30–70%) 
[1] and are associated with depression [2], lower health-
related quality of life [3, 4], socio-economic factors, and 
increased use of healthcare services [4].
Many were uncertain about how best to manage symp-
toms after the publication of the Women’s Health Initia-
tive (WHI) studies in 2002 and 2004 [5, 6]. These studies 
tested the heart-protective effect of hormone therapy 
(HT) in women who were older (50–79 years) than those 
in earlier studies (45–64  years) [7, 8]. WHI 2002 was 
prematurely terminated after HT use by women with 
an intact uterus was unexpectedly associated with an 
increased risk of breast cancer, with no apparent ben-
eficial cardiovascular effects [5]. Widespread negative 
media coverage led to a substantial and rapid decrease in 
HT use worldwide [9]. Many women ceased HT abruptly, 
with some recommencing HT due to intolerable symp-
toms [10]. A second WHI study of estrogen therapy (ET) 
in women with a hysterectomy was also prematurely 
terminated due to an increased risk of stroke with no 
increase in breast cancer risk [6] yet these conflicting 
findings were largely ignored by the media. Subsequent 
reanalysis found that both studies were confounded by 
age [11] with a ‘window of opportunity’ for cardiovas-
cular health benefits if HT was initiated before 60 years 
or within ten years of menopause [11]. The 2016 Revised 
Global Consensus Statement on Menopausal Hormone 
Therapy [12] reaffirmed that HT remains the most effec-
tive treatment for vasomotor symptoms and significantly 
lowers the risk of osteoporosis-related fractures in post-
menopausal women. HT is effective in vulvovaginal atro-
phy and may improve sexual function and other related 
symptoms such as joint and muscle pains, mood changes 
and sleep disturbances. However, prescriptions for HT 
have continued to tumble. Unfortunately, the WHI 2002 
findings in older women with an intact uterus were gen-
eralised to all forms of HT, including estrogen alone in 
younger hysterectomised women. Prescriptions for HT 
declined steeply, with estimates that within 18 months of 
WHI 2002, half of US women using systemic HT stopped 
treatment. [13] Sarrel and colleagues [14] used WHI 2004 
data [15] indicating a higher rate of mortality among 
hysterectomised women aged 50 to 59  years assigned 
to placebo than estrogen over a 10-year follow-up, to 
determine how this rate of excess mortality translated 
into an aggregate toll of premature death through estro-
gen avoidance at the population level (2002–2011). Their 
analysis concerningly suggested that between 18,601 and 
91,610 excess deaths occurred among hysterectomised 
women aged 50–59 years following the publication of the 
original WHI.
Although some women continue to use HT [16], as an 
alternative to HT, many women also use herbal medicines 
(HM) [17] antidepressants [17], GABAergic agents [17], 
clonidine [17], and non-pharmacological approaches for 
VMS [18]. The changing HT evidence and multiple treat-
ment options (including no treatment) have made deci-
sion-making more complex [19, 20].
Women are taking a greater role in decisions about 
managing symptoms [21]. The consumer’s role seems 
to dominate the clinician’s when deciding on preferred 
treatment [21] but professional guidance is still needed 
and often sought when evidence of efficacy, safety, and 
multiple treatment options add to confusion [19, 20]. 
However, the legacy of the WHI studies persists. Despite 
hormone therapy  being effective in reducing all-cause 
mortality [22], many women seeking relief of menopausal 
symptoms exaggerate HT harms, overstate the perceived 
benefits of alternative therapies, or ignore their risks 
[23–25].
Women’s decision-making processes in managing men-
opause have been modelled in normal [19] and surgical 
menopause [20]. Existing models suggest decision-mak-
ing is driven by both internal (e.g. individual charac-
teristics, values, attitudes, beliefs and preferences) and 
external factors (e.g. healthcare provider context, facts 
and information) [19, 20] but these models have limita-
tions. Evidence was collated mainly from cross-sectional 
studies, with many conducted pre-WHI 2002 [19, 20]. 
There are comparatively few recent studies focusing on 
women in the active process of decision-making [24, 26].
Women seek information to manage their health from 
a range of sources including social networks, social 
media, and the internet [9, 27]. Some women may be 
uncomfortable using the internet, preferring immediate 
feedback or an opportunity to ask questions and discuss 
potentially opposing ideas [28, 29]. Where consultation 
time is limited, others might be reluctant to be perceived 
is complex and dynamic. Reassurance to reach or justify decisions from a perceived trusted source can support 
informed decision-making.
Keywords: Menopause, Estrogen replacement therapy, Information seeking behaviour, Decision making, Drug 
information services
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as ignorant or question their clinician’s judgement [30]. 
A consumer medicines call centre (MCC) operated by 
pharmacists provides an alternative, anonymous source 
for obtaining reliable and evidence-based medicines 
information [31].
We sought to understand the information-seeking 
and decision-making behaviour of women accessing a 
MCC with menopause symptom management concerns, 
as evidence changed over time. We aimed to: (1) longi-
tudinally explore the impact of WHI 2002 on women’s 
information-seeking behaviours (2) compare informa-
tion-seeking for HT and menopause-related HM, and (3) 




We longitudinally analysed routinely-collected health 
service data from two Australian MCCs operated by 
clinical pharmacists from Mater Health, Brisbane: (1) 
Queensland Medication Helpline (QMH), a state-wide 
service operating from July 1996 to September 2002, i.e. 
pre-WHI and two months post-WHI 2002; and (2) NPS 
MedicineWise, formerly the National Prescribing Service 
(NPS) Medicines Line (ML), a nationwide service, Sep-
tember 2002–June 2010. Together these datasets provide 
continuous, longitudinal data over 14  years; and can be 
divided into three time periods (Fig. 1):
• Time 1 Pre-WHI 2002 (June 1996–9 July 2002), men-
opause-related calls were only 4.1% of all calls, most 
related to HT only.
• Time 2 WHI 2002 publication and associated nega-
tive media (10 July–19 September 2002), menopause-
related calls increased to 16.6% of all calls.
• Time 3: post-WHI (20 September 2002–30 June 
2010), menopause-related calls decreased to 0.3% of 
Queensland and 0.4% of calls from the rest of Aus-
tralia.
We quantitatively and qualitatively analysed these 
data. The time ranges were identical for Time 1 and 
Time 3; but we used a deliberately narrower ‘window’ 
(10–26 July 2002, Time 2a) for the qualitative analy-
sis (Fig.  1) to capture questions and concerns in the 
period immediately following WHI 2002 and the media 
response. During these 13 service days, QMH phar-
macists kept detailed information on callers’ men-
opause-related questions and concerns—some with 
overwhelming anxiety—and any actions prior to service 
contact.
We conducted and reported this research in accord-
ance with the REporting of studies Conducted using 
Observational Routinely-collected health Data 
(RECORD) guideline [32]. We had ethical approval 
from the Mater Health Services Human Research Eth-
ics Committee (HREC/13/MHS/80).
Fig. 1 Flow chart describing the datasets explored in the study; critical time-points; data subset by state and medicine type-related calls, and; 
quantitative variables and call narratives obtained for analysis. WHI = Women’s Health Initiative study, HT = hormone therapy, HM = herbal 
medicines, ACR = annualised call rate
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Data collection
Call data were recorded manually on a scannable col-
lection form and transformed into an electronic data-
set. Most variables were consistently recorded over 
time, including caller and patient demographic charac-
teristics, question enquiry type, call motivation, medi-
cines involved, the question, and answer. Question 
narratives were only electronically recorded in selected 
periods due to limited funding but we hand-searched 
forms for additional narratives across the study period.
Data classification
Medicines of interest were mapped to the Anatomi-
cal Therapeutic Chemical code: [33] G03CA (estro-
gens), GO3F (estrogen plus progestogen therapy, EPT), 
G03CX01 (tibolone), and G03BA03 (testosterone). 
We filtered data from female consumers by age to 
include calls from women who might experience pre-
mature menopause: ≥ 35  years for women calling for 
estrogen therapy and ≥ 48  years for EPT; calls were 
considered’rest of calls’ (ROC) if patient age was under 
the cut-off. We filtered the testosterone calls by patient 
gender (‘female’ or ‘blank’) to enhance call retrieval and 
we excluded non-menopause data. We examined calls 
for five HM: black cohosh, wild yam, soy-based prod-
ucts, chaste tree, and red clover.
Variables of interest
We extracted data on variables: gender and age of the 
caller and patient, caller-patient relationship (self, 
partner, parent, child, other family, friend and client), 
enquiry type, call motivation, and postcode. Pharma-
cists classified the enquiry type and call motivation 
into predetermined categories [31]. We collapsed the 
21 enquiry types into seven groups: (1) side effects, (2) 
risk/benefit, (3) pragmatics of use (e.g. administration, 
dose, withdrawal and efficacy, and stability/storage/
disposal), (4) interactions, (5) mechanism/profile (e.g. 
indication, identification, formulation), (6) treatment/
prophylaxis, and (7) logistics and miscellaneous (e.g. 
availability, comparison, cost, generic, subsidised medi-
cines). The 17 call motivations were collapsed into  six 
groups: (1) inadequate information, (2) second opinion, 
(3) worrying symptoms, (4) conflicting information, 
(5) the media and (6) other. We mapped caller post-
code to the Accessibility/Remoteness Index of Australia 
(ARIA), which measures the remoteness of areas from 
service centers [34, 35]. We compared proportions of 
calls from each ARIA with population data to generate 
relative call frequencies expressed as a ratio [34, 35].
Analysis
Quantitative analysis
We compared menopause-related calls and ROC over 
time and by medicines class (HT and HM). Some data 
(QMH) were only from Queensland so we assessed 
whether call characteristics differed between Queens-
land and other states in the Australian (ML) dataset and 
between Queensland callers of QMH and ML, respec-
tively. We used a one-way analysis of variance (ANOVA) 
and Pearson’s chi-square test to test for any differences. 
We conducted post-hoc analyses, including Tukey’s hon-
esty significant test and standardised residuals method 
[36], to further explore any differences among categories. 
We applied the Bonferroni correction to a p-value of 0.05 
to avoid false-positive results [36]. We used Microsoft 
Excel 365 (Microsoft, Redmond, WA, USA) and SPSS 
(version 25.0, IBM Corp, Armonk, NY, USA).
Qualitative narratives
The purpose of the qualitative data analysis was to pro-
vide further insight into the results of our quantitative 
analyses. All question narratives were collected and ana-
lysed thematically according to the results identified in 
our quantitative analyses. We used a system of coding, 
comparison, and clustering with a basic coding frame 
developed from our quantitative results [37]. To enhance 
the rigour of this analysis two coders separately coded 
each question narrative. Any discrepancies or revisions 
to coding were resolved through consensus.
Results
Impact of the WHI 2002 publication on call characteristics
Most menopause-related calls were made by women in 
their mid-50s (average 56.5–59.3 years) from areas clas-
sified as either highly accessible or accessible, and seek-
ing help for themselves (Table  1). Call characteristics 
were compared among: (1) menopause-related and ROC 
over time; (2) Queensland and other states in the Aus-
tralian dataset; and (3) Queensland callers of QMH and 
ML (Additional file  1). The differences in key call char-
acteristics between menopause and ROC were consistent 
and stable over time. There were no differences in meno-
pause-related calls for caller gender, relationship between 
caller and patient, nor ARIA when we compared calls 
originating from Queensland vs other states/territories; 
or over time (Additional file 1).
Menopause-related calls surged in the two months 
after WHI 2002 (July 2002, Fig.  1); two in three calls 
(66.7%) were motivated by media reports. Prior to WHI 
2002, women were motivated to ring because of worry-
ing symptoms and inadequate information (Table  1). 
The media effect was relatively short-lived, with only 
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Table 1 Comparison of characteristics of menopause-related calls across three time periods
Comparison between group in callers’ and patients’ age was obtained from Tukey’s post-hoc analysis. Only comparison with statistically a significant result at the 
p ≤ 0.05 is presented
QMH = Queensland Medication Helpline, ML = National Prescribing Service Medicines Line, Time 1 = pre-the Women’s Health Initiative (WHI) 2002 study (1996 – 9 July 
2002), Time 2 = post-WHI 2002 (10 July – 19 September 2002), Time 3 = QMH = Queensland Medication Helpline, ML = National Prescribing Service Medicines Line, 
Time 1 = pre-the Women’s Health Initiative (WHI) 2002 study (1996 – 9 July 2002), Time 2 = post-WHI 2002 (10 July – 19 September 2002), Time 3 = QMH = Queensland 
Medication Helpline, ML = National Prescribing Service Medicines Line, Time 1 = pre-the Women’s Health Initiative (WHI) 2002 study (1996 – 9 July 2002), Time 
2 = post-WHI 2002 (10 July – 19 September 2002), Time 3 = September 2002 – June 2010, SD = standard deviation, ΔMean = mean difference between two groups, 
CI = confidence interval, ARIA = Accessibility Remoteness Index of Australia
a Value of client (carer/patient), child/friend/other family, and parent were combined to meet the assumption of Pearson’s chi-square test, i.e. less than 20% of cells 
have an expected value less than 5
b Denotes the category with column proportions that differ significantly across time-periods at the p ≤ 0.05 with Bonferroni correction
c Some QMH calls have more than one question. Proportion in this variable reflects the proportion of the number of enquiry types to total enquiry type (Time 1, 
number (n) menopause questions = 1,739; Time 2, (n) menopause = 170)
d All categories related to safety in Enquiry type
Characteristics QMH ML p-value Note
Time 1 Time 2 Time 3
(n = 742) (n = 126) (n = 961)
Callers age, years 0.004 Comparison, ΔMean (95% CI)
Mean (SD) 56.5 (9.6) 59.3 (8.5) 57.7 (10.5) Time 1 vs. Time 2: -2.80 (-5.07, -0.54)
Time 1 vs. Time 3: -1.20 (-2.35, -0.05)
Callers gender, % 0.611
Male 4.0 4.0 3.2
Female 94.2 95.2 96.8
Patients age, years 0.008 Comparison, ΔMean (95% CI)
Mean (SD) 57.1 (9.7) 59.9 (8.9) 58.0 (10.2) Time 1 vs. Time 2: -2.80 (-5.04, -0.56)
Relationship of caller, % 0.006a
Self 89.1 88.9 95.1
Partner 2.2 4.0 1.9
Client (carer/patient) a 2.0 - 1.7
Child/friend/other family a 2.8 1.6 0.8
Parent a 1.2 0.8 0.5
Call motivation, %  < 0.001
Inadequate information b 14.2 9.5 38.5
Second opinion 14.7 8.7 24.5
Worrying symptom 22.2 4.8 19.7
Conflicting information 7.8 0.8 8.8
Other 13.5 1.6 6.8
Media b 7.4 66.7 1.3
Enquiry type, %c  < 0.001
Side effects d 24.8 15.9 23.2
Pragmatics of use 16.2 14.1 11.8
Treatment/prophylaxis 13.4 8.2 8.5
Risk/benefit b,d 12.7 46.5 17.4
Logistics and miscellaneous 12.7 8.2 9.4
Mechanism/profile 12.5 4.7 14.4
Interaction b,d 7.6 2.4 15.1
Enquiry type—safety 45.1 64.8 55.7
ARIA index, relative call frequencye 0.209
Highly accessible 1.14 1.17 1.22
Accessible 0.55 0.46 0.48
Moderately accessible 0.48 0.44 0.32
Remote 0.42 - 0.53
Very remote 0.56 0.80 1.00
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13 questions (~ 2  calls/year) prompted by media after 
September 2002. Information gaps or concerns about 
medication safety were the primary reasons for calling, 
irrespective of time. Safety enquiries ranged from 45 to 
65%, with the highest frequency immediately after WHI 
2002 largely due to an increase in queries about HT’s 
risks versus benefits (Table 1).
Calls about menopause-related HM were few: only 
8.4% before WHI 2002 and 18.6% later on (Fig. 1). Only 
two of 126 callers asked a question about HM at immedi-
ately after WHI 2002 when HT concerns predominated. 
After September 2002, one in three (34.7%) HM calls 
concerned interactions (Table 2).
Menopause narratives
We identified four primary themes (safety concerns, prag-
matics of use, therapy options, and regimen comparisons) 
and 17 sub-themes from 749 menopause-related calls. 
There were 846 total questions (some narratives had 
more than one question): 229 from before WHI (Time 1), 
70 immediately after WHI (Time 2a), and 547 from Sep-
tember 2002 (Time 3). The nature of calls varied across 
the periods, but safety concerns predominated (59.4% 
Time 1, 98.6% Time 2a, 65.3% Time 3), with women tend-
ing to overestimate HT risk (Table 3). Immediately after 
WHI 2002 negative media coverage (Time 2a), one in 
three (32%) callers (32%) were particularly concerned 
about breast cancer. Many had abruptly ceased, or were 
seeking reassurance to cease, their HT (including women 
who had had a hysterectomy) because of breast cancer 
fears.
48-year-old woman - four years since she had a 
breast cancer removed.
“I’m really worried about taking estrogen in case it 
reactivates my breast cancer, but I just want to treat 
my terrible tiredness and hot feelings. What should 
I do?”
Sometimes the cancer fear was transferred to other 
symptoms or concerns. Following his wife’s death from 
heart failure, a 60-year-old male was concerned that HT 
might have been the underlying cause (Table  3). Breast 
cancer was mentioned at other time periods; it was not 
a fear of the disease per se but to decide whether they 
could (or should) use HT or an alternative strategy.
Women asking for help to balance the risks and ben-
efits to either use or withdraw HT, based on their individ-
ual circumstances, was a particular feature immediately 
after WHI (Time 2a); while before WHI and later, there 
was a focus on clarifying the cause of a particular symp-
tom in relation to HT. Before and later after WHI women 
more commonly sought reassurance to use HT with 
other medicines or in the presence of other diseases.
Pragmatics of use ranked highly in Times 1 and 3, 
where changes in medicines access, particularly in later 
years, prompted a need for decision-making. Similarly, 
calls about therapy options and regimen comparisons at 
Times 1 and 3 were not evident at Time 2a. Over time, the 
nature of HT safety questions evolved to include whether 
vaginal HT produced similar effects to systemic HT (oral 
or transdermal) and calls asking for alternative forms 
of treatment. For non-hormone therapy, women asked 
whether HM, antidepressants, or bisphosphonates were 
effective in managing menopause. Women older than 
60 years sought reassurance to use HT across the period 
of our study (1996–2010) despite guidelines after 2002 
deeming HT unsuitable for this cohort [38] (Table 3).
Our data demonstrated the complex and dynamic 
interplay of internal and external factors that influence 
women who seek information for reassurance, to reach 
or justify a decision about managing menopause symp-
toms (Fig. 2). Information-seeking occurred in response 
to heightened uncertainty: worrying symptoms, therapy 
dissatisfaction, inadequate or conflicting information, 
perceived risk, or change to treatment availability. Any 
ambiguity stimulated decision reassessment. The more 
intense the uncertainty (e.g. negative media about HT), 
the more women relied on emotions to emphasise risk 
over benefit. Selected vignettes highlight the iterative 
nature of this decision-making (Additional file 2).
Discussion
WHI 2002 [5] was the ‘top medical story of 2002’, cre-
ating the ‘HT scare’ [9]. Negative media was the main 
driver of information-seeking for decision-making; calls 
increased 400% in the first two weeks and remained high 
for the subsequent two months. Maladaptive risk per-
ception is a cornerstone of cognitive models of decision 
making under risk and uncertainty, where worried indi-
viduals generally overestimate negative outcomes [39], 
and emotional reactions to perceived risk often diverge 
from cognitive assessments of those risks, driving behav-
iours such as help-seeking [40]. While the effect on help-
seeking was relatively short-lived, consumer concerns 
about safety persisted for years after WHI 2002. Despite 
subsequent media reports of HT benefits [9] in specified 
cohorts [11], there were few calls prompted by media 
e Relative call frequency was calculated by dividing the proportion of calls by proportion of population in the specific ARIA index
Table 1 (continued)
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reports after 2006. In an invited review about media and 
the consumer, Shapiro highlighted the pervasive impact 
of media on public perceptions of risk, citing Vincent 
Covello (Center for Risk Communication, Columbia 
University): “research has shown that strong beliefs about 
risk, once formed, change very slowly and are extraordi-
narily persistent in the face of contrary evidence.’’ [41]
Table 2 Comparison of call characteristics between menopause-related calls about hormone therapy and herbal medicines across 
three time periods
Time 1 = pre-the Women’s Health Initiative (WHI) 2002 study (1996 – 9 July 2002), Time 2 = post-WHI 2002 (10 July – 19 September 2002), Time 3 = September 2002 – 
June 2010, HT = hormone therapy, HM = herbal medicine, SD = standard deviation, ARIA = Accessibility Remoteness Index of Australia
A only two calls asking about hormone therapy and herbal medicines in Time 2
b Some calls from Queensland Medication Helpline have more than one question recorded. The proportion in this variable reflects the proportion of the number of 
enquiry type to total enquiry type (Time 1, number of questions (n) HT only = 1,547, HT and HM = 63, HM only = 129; Time 2, n HT and HM = 170)
c Relativecall frequency was calculated by dividing the proportion of calls by the proportion of population in the specific ARIA index
Characteristics Queensland Medication Helpline NPS Medicines Line
















Mean (SD) 56.7 (9.8) 53.3 (7.9) 56.6 (5.8) 59.5 (8.5) 58.6 (10.6) 53.3 (9.4) 56.0 (5.8)
Caller gender, %
Male 3.8 - 9.3 4.0 3.3 3.2 2.7
Female 94.4 100.0 88.4 95.2 96.7 96.8 97.3
Patients age, years
Mean (SD) 57.4 (9.9) 53.1 (7.5) 56.3 (5.8) 59.9 (8.9) 58.8 (10.5) 54.0 (8.7) 55.9 (5.8)
Relationship of caller, %
Self 89.1 94.7 86.0 88.9 95.8 96.8 91.2
Partner 2.1 - 4.7 4.0 1.8 3.2 2.0
Client (carer/patient) 1.9 5.3 2.3 - 1.3 - 4.1
Child/friend/other family 2.6 - 7.0 1.6 0.8 - 1.4
Parent 1.3 - - 0.8 0.4 - 1.4
Call motivation, %
Inadequate information 13.7 10.5 23.3 9.5 37.2 41.9 44.6
Second opinion 14.6 21.1 14.0 8.7 24.4 25.8 24.3
Worrying symptom 23.5 5.3 9.3 4.8 21.2 19.4 11.5
Conflicting information 7.9 5.3 7.0 0.8 9.3 - 8.1
Other 13.1 26.3 11.6 1.6 6.4 12.9 7.4
Media 6.9 10.5 14.0 66.7 1.0 - 3.4
Enquiry Type, %b
Side effects 25.8 17.1 17.5 16.2 25.8 19.4 18.2
Pragmatics of use 15.6 20.9 22.2 13.8 15.6 9.7 14.2
Treatment/prophylaxis 13.8 9.3 11.1 8.4 13.8 12.9 6.8
Risk/benefit 12.4 14.0 17.5 46.7 12.4 19.4 16.9
Logistics and miscellaneous 13.1 8.5 9.5 8.4 13.1 12.9 0.7
Mechanism/profile 11.9 17.8 17.5 4.2 11.9 9.7 8.1
Interaction 7.4 12.4 4.8 2.4 7.4 12.9 34.5
ARIA index, relative call frequencyc
Highly accessible 1.13 1.08 1.19 1.16 1.23 1.23 1.17
Accessible 0.53 0.83 0.38 0.46 0.42 0.16 0.81
Moderately accessible 0.51 0.21 - 0.44 0.31 1.08 0.30
Remote 0.43 - 1.77 - 1.00 - -
Very remote 0.45 1.15 - 0.40 0.90 - -
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The subsequent  HT-favourable findings of cardiovas-
cular benefit in selected cohorts [11] did not elicit the 
same level of public attention as WHI 2002. Women’s 
perception may have been influenced by other informa-
tion sources (e.g. peers and clinicians) [9] or may reflect 
persistent concern about breast cancer [11]. Our findings 
support the notion that the fear of cancer overshadowed 
any beneficial effect of HT on cardiovascular health [42].
There were proportionally fewer menopause-related 
calls over time. While this might simply reflect lower HT 
use due to progressive product withdrawals after 2002, 
few studies assessing the relationship between product 
withdrawal and use could be retrieved [42–44]. In addi-
tion, distrust in medical science, given the ‘pendulum 
swings’ in HT evidence [21], potentially left women feel-
ing they had no alternative but to bear with their symp-
toms without pharmacological intervention [27].
We found that women considering menopause therapy 
sought reassurance about their decision-making before 
and after WHI 2002, but their priorities differed. After-
wards, women were more likely to seek confirmation that 
HT or HM were safe to use with their other medicines, 
suggesting increased interest in HM as a substitute for 
HT [24, 27]. The potential for interactions with over-the-
counter medicines such as HM is a concern for consum-
ers who self-medicate without consulting their clinician 
[45]. Women with severe menopausal symptoms might 
also experience other symptoms [2], or use more health-
care services [4], which may mean use of medicines other 
than HT. There may have also been a change in the treat-
ment objective. Before WHI 2002 some clinicians pre-
scribed HT for women who were symptom free; while 
afterwards HT use was largely limited to patient requests 
for symptom relief [21].
We found that changes in treatment access or avail-
ability influenced information-seeking behaviour and 
prompted women to seek substitute treatment. After 
WHI 2002, women requested information on substi-
tute treatments when HT products were progressively 
removed from government subsidy and subsequently the 
Australian market. Calls about HM primarily originated 
from areas with good access to service centres where a 
pharmacy, health store, or naturopath are more likely to 
be located. Our finding is consistent with a survey of HM 
use by 2,020 Australian middle-aged women which found 
a higher prevalence of HM use for menopausal symp-
toms among women residing in metropolitan areas [46] 
perhaps reflecting increased availability and income.
To our knowledge, no other study has examined wom-
en’s information-seeking and decision-making about 
managing menopause before and for more than seven 
years after WHI 2002. These data reflect the real-world 
issues faced by women and the significant impact of neg-
ative media reporting. The study’s longitudinal nature 
also allowed us to examine any persisting impact of WHI 
2002.
We acknowledge some study limitations. The data 
were collected as part of routine MCC activity so there 
Fig. 2 Decision-making model in menopause management. New factors or processes observed in this study when compared to previous 
decision-making models [19, 20] are in bold dashed-line and dashed-line boxes
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was no opportunity to prospectively collect additional 
data of interest. The MCCs were in Australia, so our 
results might not reflect the concerns of women in other 
places with different cultures and ethnicities. Indications 
for medicines were not captured, so we were unable to 
explore concerns about the use of non-hormone therapy 
for menopause [17]. The two data sources might not be 
fully comparable given the differences in coverage and 
time frames. Our study period ended in 2010, prior to the 
Global Consensus Statement on Menopausal Hormone 
Therapy in 2013 [47]—the official reassurance made by 
various medical societies about the safe use of HT in spe-
cific cohorts of women. We need to know more about 
women’s information needs for all available treatments, 
especially after 2013.
Building on previous models of decision-making in 
menopause [19, 20], we identified that women informa-
tion-seek for reassurance from a trusted source, to assist 
or justify a decision [48]. This is influenced by heightened 
intolerance to risk, associated with a change in competing 
internal factors (woman’s specific symptom concerns and 
tolerance to risk), and external factors (the impact of neg-
ative or conflicting information, source trust and product 
availability (Fig.  2). Decision-making is an iterative pro-
cess. Accessing HT or other therapy involves a discourse 
between a woman and her clinician but we observed that 
women sought information or reassurance to support a 
new decision based on dynamic changes in internal (e.g. 
experiencing a side effect or new symptoms) and exter-
nal factors (including conflicting medical advice) about 
how she will ultimately manage her symptoms. Nega-
tive or conflicting source information, worrying symp-
toms, perceived treatment risk, and decreased treatment 
availability contribute to perceived risk predominance. 
If other factors emerge that change the dynamics of the 
decision-making process, the iterative cycle will recom-
mence (Fig. 2).
Conclusions
Negative WHI 2002 media reports escalated infor-
mation-seeking for decision-making about managing 
menopausal symptoms. While safety concerns and over-
estimation of risk persisted, the factors influencing the 
nature and intensity of information-seeking changed over 
time and over the woman’s menopause journey, requir-
ing reconsideration of previous decisions. Reassurance to 
reach or justify decisions from a perceived trusted source 
can support informed and shared decision-making.
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